

1. Boyko A, Kesselring J, Paty DW, Siva A, Singhal B, Thompson A, Willoughby E. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders, 1999, (2), 1-11
2. Boyko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, the UBC MS Clinic Neurologists. Early onset multiple sclerosis: A longitudinal study. *Neurology* 2002, 59: 1006-1010
3. Paty DW, Boyko AN, Vorobeychik GK. Multiple sclerosis with early and late disease onset. Chapter 18 in: "Multiple sclerosis 2. Blue book of Practical Neurology #27", eds. W.I.McDonald and J.H.Noseworthy Elsevier Science, Butterworth Heinemann, Philadelphia, PA, 2003: 285-302
4. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; Boyko A, FORTE Study Group Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. *Ann Neurol*. 2011; 69(1): 75-82
5. Kulakova OG, Tsareva EY, Boyko AN, Shchur SG, Gusev EI, Lvovs D, Favorov AV, Vandembroek K, Favorova OO. Allelic combinations of immune-response genes as possible composite markers of IFN- β efficacy in multiple sclerosis patients. *Pharmacogenomics*. 2012; 13(15): 1689-1700
6. Belogurov AA Jr, Stepanov AV, Smirnov IV, Melamed D, Bacon A, Mamedov AE, Boitsov VM, Sashchenko LP, Ponomarenko NA, Sharanova SN, Boyko AN, Dubina MV, Friboulet A, Genkin DD, Gabibov AG. Liposome-encapsulated peptides protect against experimental allergic encephalitis. *FASEB J*, 2013; 27(1): 222-231
7. Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdová E, Hommes O, Leloirier J, Morrow SA, Oreja-Guevara C, Rijke N, Schippling S. Future MS care: a consensus statement of the MS in the 21st Century Steering Group. *J Neurol*. 2013, 260 (2): 462-469
8. Sokolova EA, Malkova NA, Korobko DS, Rozhdestvenskii AS, Kakulya AV, Khanokh EV, Delov RA, Platonov FA, Popova TY, Aref'eva EG, Zagorskaya NN, Alifirova VM, Titova MA, Smagina IV, El'chaninova SA, Popovtseva AV, Puzyrev VP, Kulakova OG, Tsareva EY, Favorova OO, Shchur SG, Lashch NY, Popova NF, Popova EV, Gusev EI, Boyko AN, Aulchenko YS, Filipenko ML. Association of SNPs of CD40 gene with multiple sclerosis in Russians. *PLoS One*. 2013; 8(4): e61032
9. Lomakin YA, Zakharova MY, Belogurov AA, Bykova NA, Dronina MA, Tupikin AE, Knorre VD, Boyko AN, Favorov AV, Kabilov MR, Ponomarenko NA, Gabibov G. Polyreactive monoclonal autoantibodies in multiple sclerosis: functional selection from phage display library and characterization by deep sequencing analysis. *Acta Naturae*. 2013; 5(4): 94-104
10. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; on behalf of the ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. *J Neurol Neurosurg Psychiatry*. 2014, 85: 852-859
11. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A. Pegylated interferon beta-1a in relapsing-remitting multiple sclerosis (ADVANCE): a randomized, phase 3, double-blind study. *Lancet Neurol*, 2014; 13(7): 657-665
12. Kulakova OG, Tsareva EY, Lvovs D, Favorov AV, Boyko AN, Favorova OO. Comparative pharmacogenetics of multiple sclerosis: IFN- β versus glatiramer acetate. *Pharmacogenomics*. 2014; 15(5): 679-685
13. Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Orolugas A, Otero-Romero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-

- Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Ozgür Y. Multiple sclerosis registries in Europe - results of a systematic survey. *Mult Scler.* 2014; 20(11): 1523-1532.
14. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J; ATAMS Study Group. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Neurol.* 2014; 13(4): 353-363
 15. Belova AN, Shalencov IV, Shakurova DN, Boyko AN. Revised McDonald criteria for multiple sclerosis diagnostics in Central Russia: Sensitivity and specificity. *Mult Scler. J* 2014, 20(14), 1896-1899
 16. Bashinskaya V.V., Kulakova O.G., Boyko A.N., Favorov A.V., Favorova O.O. A review of genome-wide association studies for multiple sclerosis: classical and hypothesis-driven approaches. *Hum Genet* 2015; 134 (11-12): 1143-1162
 17. Kappos L., Wiendl H., Selmaj K., Arnold D.L., Havrdova E., Boyko A., Kaufman M., Rose J., Greenberg S., Sweetser M., Riestler K., O'Neill G., Elkins J. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Eng J Med* 2015, 373, 15: 1418-1428
 18. Boyko A. Long-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation. *Multiple Sclerosis & Demyelinating Diseases* 2016: 1:14 DOI 10.1186/s40893-016-0015-x
 19. Boyko A, Smirnova N, Petrov S, Gusev E. Epidemiology of MS in Russia, a historical review. *Multiple Sclerosis & Demyelinating Diseases* 2016: 1:13 DOI 10.1186/s40893-016-0016-9
 20. Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. *Neurology.* 2016; 87(19): 1985-1992 IF=8,166